GSTs, MRP and Apoptototic Markers in DLD-1 Human Colon Cancer Cell Line Before and After 5-FU Treatment

Abstract

Multidrugresistance is an important factor limiting the effect of chemotherapy on cancer treatment. Disorders of drug transport and apoptosis, deterioration of redox homeostasis are among the main mechanisms that lead to multidrug resistance. The aim of this study was to determine the effect of 5-FU on GST isozymes, drug resistance proteins and apoptotic proteins before and after 5-Flourouracil application on DLD-1 colon cancer cell line. The cytotoxic effect of 5-FU was measured by WST-1test and, the efficiency of drug application was, also, proved by double staining via Hoechst 33342 with Propidium iodide. Next, the expression levels of GST isozymes, drug resistance proteins and apoptotic proteins were determined by immunocytochemistry. The cytotoxic effect of 5-FU at different doses on DLD-1 colon cancer cell line was determined by WST-1 method. MRP-2, 3, 6, 7 of drug resistance proteins; GSTA1, GSTM1, GSTT1, GSTZ1, GSTK1 and GSTO1 of GST proteins; bcl-2, caspase-3, p38, and p53, which are apoptotic proteins, have higher expression in the drug-treated DLD-1 cell line. GSTS1, MDR-1 and MRP-1expressions were not immunocytochemically different. It was determined that there is a direct correlation between the level of cytotoxicity and applied drug concentration. The cytotoxic effect of the drug increased with the increase in the dose of the drug. In this study, as first in the literature, the expression levels of some apoptotic markers, GST isozymes and drug resistance proteinswere evaluated togetherand except GSTS1, MDR-1 and MRP-1, they were all upregulated with respect to the control group after 5-FU administration.

Keywords

• Multidrug resistance
• GST isozymes
• apoptosis
• MRP
• 5-FU
• DLD-1.

References

1. Ahnen, D. J., Feigl, P., Quan, G., Feneoglio-Preiser, C., Lovata, L. C., Bunn, P. A., Stemmerman, G., Wells, J. D., Macdonald, J. S., & Meyskens, Jr., F. L. (1998). Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Research, 58, 1149-1158.
2. Baguley, B. C. (2010). Multidrug resistance in cancer. Methods Molecular Biology 596, 1-14. https://doi.org/10.1007/978-1-60761-416-6_1
3. Bahrami, A., Amerizadeh, F., Hassanian, S., M., ShahidSales, S., Khazaei, M., Maftauh, M., Ghayour-Mobarhan, M., Ferns, G. A., & Avan, A. (2018). Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin‐based chemotherapy. Journal of Cellular Physiology, 233(3), 2193-2201. https://doi.org/10.1002/jcp.25966
4. Cancer Today [Internet]. (2021), [cited 2021 Jun 30]. Available from: https://gco.iarc.fr/today/fact-sheets-cancers
5. Chao, C. C., Huang, Y. T., Ma, C. M., Chou, W. Y., & Lin-Chao, S. (1992). Overexpression of glutathione S-transferase and elevation of thiol pools in a multidrug-resistant human colon cancer cell line. Molecular Pharmacology, 41(1), 69-75.
6. Choi, J. H., Yoon, J. S., Won, Y. W., Park, B. B., & Lee, Y. Y. (2012). Chloroquine enhances the chemotherapeutic activity of 5-fluorouracil in a colon cancer cell line via cell cycle alteration. Acta Pathologica, Microbiologica, et Immunologica Scandinavica, 120(7), 597-604. https://doi.org/10.1111/j.1600-0463.2012.02876.x
7. Cunningham, D., Atkin, W., Lenz, H. J., Lynch, H. T., Minsky, B., Nordlinger, B., & Starling, N. (2010). Colorectal cancer. Lancet, 375, 1030-1047. https://doi.org/10.1016/S0140-6736(10)60353-4
8. Çiftçi, H., Türk, M., Tamer, U., Karahan, S., & Menemen, Y. (2013). Silver nanoparticles: cytotoxic, apoptotic, and necrotic effects on MCF-7 cells. Turkish Journal of Biology, 37, 573-581. https://doi.org/10.3906/biy-1302-21

9. Dang, D. T., Chen, F., Kohli, M., Rago, C., Cummins, J. M., & Dang, L. H. (2005). Glutathione S-transferase pi1 promotes tumorigenicity in HCT116 human colon cancer cells. Cancer Research, 65(20), 9485-9494. https://doi.org/10.1158/0008-5472.CAN-05-1930
10. Dongxing, C, Shaolan, Q., Mu, Y., & Ming, Z. (2017). The role of MRP1 in the multidrug resistance of colorectal cancer. Oncology Letters, 13, 2471-2476, https://doi.org/10.3892/ol.2017.5741
11. Elsaleh, H., Powell, B., McCaul, K, Grieu, F., Grant, R., Joseph, D., & Lacopetta, B. (2001). P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clinical Cancer Research, 7, 1343-1349.
12. Fiore, D., Proto, M. C., Pisanti, S., Picardi, P., Pagano Zottola, A. C., Butini, S., Gemma, S., Casagni, A., Laezza, C., Vitale, M., Ligresti, A., Di Marzo, V., Zisterer, D. M., Nathwani, S., Williams, D. C., Campiani, G., Gazzerro, P., & Bifulco, M. (2016). Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells. Cancer Biology & Therapy, 17(8), 849–858. https://doi.org/10.1080/15384047.2015.1078028
13. Fojo, A., Hamilton, T. C., Young, R. C., & Ozols, R. F. (1987). Multidrugresistance in ovarian cancer. Cancer, 60, 2075–80. https://doi.org/10.1002/1097-0142(19901015)60
14. Geng, M., Wang, L., & Peifeng, L. (2013). Correlation between chemosensitivity to anticancer drugs and Bcl-2 expression in gastric cancer. International Journal of Clinical and Experimental Pathology, 6(11), 2554-2559.
15. Ghafouri-Fard, S., Abak, A., TondroAnamag, F., Shoorei, H., Fattahi, F., Javadinia, S. A., Basiri, A., & Taheri, M. (2021). 5-Fluorouracil: A narrative review on the role of regulatory mechanisms in driving resistance to this chemotherapeutic agent. Frontiers in Oncology, 11, 658-636. https://doi.org/10.3389/fonc.2021.658636
16. Gong, J., Jaiswal, R., Mathys, J-M., Combes, V., Grau, G. E. R., & Bebawy, M. (2012). Microparticles and their emerging role in cancer multidrug resistance. Cancer Treatment Reviews, 38, 226–234. https://doi.org/10.1016/j.ctrv.2011.06.005
17. Gong, R. H., Yang, D. J., Kwan, H. Y., Lyu, A. P., Chen, G. Q., & Bian, Z. X. (2022). Cell death mechanisms induced by synergistic effects of halofuginone and artemisinin in colorectal cancer cells. International Journal of Medical Sciences, 19(1), 175-185. https://doi.org/10.7150/ijms.66737
18. Gottesman, M. M., & Living, V. (2006). The moleculer basis of multi drug resistanace in cancer; the early years of P-glycoprotein research. European Biochemical Societies Letter, 580, 998-1009. https://doi.org/10.1016/j.febslet.2005.12.060
19. Gottesman, M. M., Fojo, T., & Bates, S. E. (2002). Multidrugresistance in cancer: role of ATP-dependent transporters. Nature Reviews Cancer, 2, 48–58.
20. Hoban, P. R., Robson, C. N., Davies, S. M., Hall, A. G., Cattan, A. R., Hickson, I. D., & Harris, A. L. (1992). Reduced topoisomerase II and elevated alpha class glutathione S-transferase expression in a multidrug resistant CHO cell line highly cross-resistant to mitomycin C. Biochemical Pharmacology 43(4), 685-93. https://doi.org/ 10.1016/0006-2952(92)90231-7
21. Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013). Cancer drug resistance: an evolving paradigm. Nature Reviews Cancer, 13, 714-726. https://doi.org/ 10.1038/nrc3599
22. Jung, J. H., Taniguchi, K., Min Lee, H., Young Lee, M., Bandu, R., Komura, K., Yeon Lee, K., Akao, Y., & Pyo Kim, K. (2020). Comparative lipidomics of 5-Fluorouracil–sensitive and –resistant colorectal cancer cells reveals altered sphingomyelin and ceramide controlled by acid sphingomyelinase (SMPD1). International Journal of Scientific Reports, 10, 6124. https://doi.org/10.1038/s41598-020-62823-0
23. Khoo, E., O’Neill, S., Brown, E., Wigmore, S. J., & Harrison, E. M. (2016). Systematic review of systemic adjuvant, neoadjuvan tand perioperative chemotherapy for resectable colorectal-liver metastases. Hepato Pancreato Biliary Association, 18(6), 485-493. https://doi.org/10.1016/j.hpb.2016.03.001
24. Koçdoğan Kaya, A., Oğuztüzün, S., Şimşek, G. G., & Türk, M. (2020). Investigation of GST isoenzymes, multi drug resistance proteins, apoptotic effect in MCF-7 human breast cancer cell line before and after doxorubucin treatment. Istanbul Gelisim University Journal of Health Sciences, 10, 1-18. https://doi.org/10.38079/igusabder.631695
25. Laborde, E. (2010). Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death. Cell Death Differ, 17, 1373–1380. https://doi.org/10.1038/cdd.2010.80
26. Liang, J. T., Huang, K. C., Cheng, Y. M, Hsu, H-Y., Cheng, A-L., Hsu, C-H., Yeh, K-H., Wang, S-H., & Chang, K-J. (2002). P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. International Journal of Cancer, 97, 451-457. https://doi.org/10.1002/ijc.1637
27. Longley, D.B., Harkin, D. P., & Johnston, P. G. (2003). 5-fluorouracil: mechanisms of action and clinical strategies. Nature Reviews Cancer, 3, 330–338.
28. Longley, D., B., & Johnston, P. G. (2005). Molecular mechanisms of drug resistance. The Journal of Pathology, 205, 275–292. https://doi.org/10.1002/path.1706
29. Morrow, C. S., Peklak-Scott, C., Bishwokarma, B., Kute, T. E., Smitherman, P. K., & Townsend, A. J. (2006). Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Molecular Pharmacology, 69(4), 1499-505. https://doi.org/10.1124/mol.105.017988
30. Nakatsu, N., Yoshida, Y., Yamazaki, K., Nakamura, T., Dan, S., Fukui, Y., & Yamori, T. (2005). Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays. Molecular Cancer Neuro Therapy, 4(3), 399-412 https://doi.org/10.1158/1535-7163.MCT-04-0234
31. Namwat, N., Amimanan, P., Loilome, W., Jearanaikoon, P., Sripa, B., Bhudhisawasdi, V., & Tassaneeyakul, W. (2008). Characterization of 5-Fluorouracil-Resistant cholangiocarcinoma cell lines. Chemotherapy, 54, 343-351. https://doi.org/10.1159/000151541
32. Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe J-P., Tong, F., Speed, T., Spellman, T. S., De Vries, S., Lapuk, A., Wang, N. J., Kuo, W-L., Stilwell, J. L., Pinkel, D., Albertson, D. G., Waldman, F. M., McCormick, F., Dickson, R. B., Johnson, M. D., Lippman, M., Etheir, S., Gazdar, A., & Gray, J. W. (2006). A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell, 10(6), 515–527. https://doi.org/10.1016/j.ccr.2006.10.008
33. Nita, E. M., Nagawa, H., Tominaga, O. Tsuno, N., Fuji, S., Sasaki, S., Fu, C. G., Takenoue, T., Tsuruo, T., & Muto, T. (1998). 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins. British Journal of Cancer, 78(8), 986–992. https://doi.org/10.1038/bjc.1998.617
34. Reipsch, F., Biersack, B., Lucas, H., Schobert, R., & Mueller, T. (2021). Imidazole analogs of vascular-disrupting combretastatin A-4 with pleiotropic efficacy against resistant colorectal cancer models. International Journal of Molecular Sciences, 22(23), 13082. https://doi.org/10.3390/ijms222313082.
35. Sau, A., Pellizzari Tregno, F., Valentino, F., Federici, G., & Caccuri, A. M. (2010). Glutathione transferases and development of new principles to overcome drug resistance. Archievs Biochemistry Biophys, 500(2), 116-122. https://doi.org/10.1016/j.abb.2010.05.012
36. Stein, A., Atanackovic, D., & Bokemeyer, C. (2011). Current standards and new trends in the primary treatment of colorectal cancer. European Journal of Cancer, 47(3 Suppl.), 312-314. https://doi.org/10.1016/S0959-8049(11)70183-6
37. Szakács, G., Paterson, J. K., Ludwig, J. A., BoothGenthe, C.,& Gottesman, M. M. (2006).Targeting multidrug resistance in cancer. Nature Reviews Drug Discovery, 5, 219–234.
38. Towsend, D. M., & Tew K. D. (2003). The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene, 22(47), 7369-7375. https://doi.org/10.1038/sj.onc.1206940
39. Van Staveren, W. C., Solís, D. Y., Hébrant, A., Detours, V., Dumont, J. E., & Maenhaut, C. (2009). Human Cancer Cell Lines: Experimental Models for Cancer Cells in Situ? For Cancer Stem Cells? Biochimica et Biophysica Acta, 1795, 92-103. https://doi.org/10.1016/j.bbcan.2008.12.004
40. Very, N., Lefebvre, T., & El Yazidi-Belkoura, I. (2017). Drug resistance related to aberrant glycosylation in colorectal cancer. Oncotarget, 9(1), 1380-1402. https://doi.org/10.18632/oncotarget.22377.
41. Violette, S., Poulain, L., Dussaulx, E., Pepin, D., Faussat, A-M.,Chambazı J., Lacorte, J-M., Staedel, C., & Lesuffleur, T. (2002). Resistance of colon cancer cellsto long-term 5-Fluorouracil exposure is corrolated to the relative levelof Bcl-2 and Bcl-XL in addition to bax and P53 status. International Journal of Cancer, 98(4), 498–504. https://doi.org/10.1002/ijc.10146
42. Xu, R., Sato, N., Yanai, K., Akiyoshi, T., Naga, İ S., Wada, J., Koga, K., Mibu, R., Nakamura, M., & Katano, M. (2009). Enhancement of paclitaxel induced apoptosis by inhibition of mitogen-activated protein kinase pathway in colon cancer cells. Anticancer Research, 29, 261-270.
43. Yang, S. Y., Miah, A., Sales, K. M., Fuller, B., Seifalian, A. M. & Winslet, M. (2011). Inhibition of the p38 MAPK pathway sensitises human colon cancer cells to 5-fluorouracil treatment. International Journal of Oncology, 38, 1695-1702. https://doi.org/10.3892/ijo.2011.982
44. Yang. Y., Huycke, M. M., Herman, T. S., & Wang X. (2016). Glutathione S-transferase alpha 4 induction by activator protein 1 in colorectal cancer. Oncogene, 35(44), 5795-5806. https://doi.org/10.1038/onc.2016.113.
45. Yasemin, A. (2010). Kanserde ilaç direncinin üstesinden gelmenin yolları: Yeni ilaçların tasarımı. Türkiye Klinikleri Journal of Medical Sciences, 30(6), 2011-2016. https://doi.org/10.5336/medsci.2010-21607
46. Zhang, R., Ah Kang, K., Piao, M. J., Kim, K. C., Zheng, J., Wen Yao, C., Cha, J. W. Hee Maeng, Y., Young Chang, W., Moon, P-G., Baek, M-C., & Won Hyun, J. (2014). Epigenetic alterations are involved in the overexpression of glutathione S-transferase π-1 in human colorectal cancers. International Journal of Oncolog, 45(3), 1275-1283. https://doi.org/10.3892/ijo.2014.